EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma

Huimin Qi, Jialin Pan, Hailong Wu iD

International Journal of Molecular Sciences · 13.07.2026 · 27 (14) · 6228

DOI: 10.3390/ijms27146228 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.07.2026. Verfasst von Huimin Qi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Immunotherapy, Bile Duct Neoplasms. Die Arbeit nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal and heterogeneous primary liver malignancy with a dismal prognosis. Approximately 70% of patients are diagnosed at locally advanced or metastatic stages, therefore missing the opportunity for curative surgery, and conventional chemotherapy offers limited survival benefits. Immunotherapy, especially immune checkpoint blockade, represents a promising strategy, yet its efficacy as monotherapy in iCCA remains modest primarily due to the profoundly immunosuppressive and desmoplastic tumor microenvironment. This review examines the immune cell infiltration landscape of iCCA, focusing on the distinct roles of lymphoid cells and myeloid cells in shaping immune evasion. We then analyze key factors affecting immune responses, such as tumor-intrinsic driver mutations, immune regulatory mechanisms, and acquired resistance. Furthermore, we summarize current clinical advances in iCCA immunotherapy, including immune checkpoint inhibitor monotherapy, bispecific antibodies, combination strategies with chemotherapy or targeted therapy, cancer vaccines, and adoptive cell therapy. Despite some progress, the overall response to immunotherapy remains suboptimal, and future strategies need to focus on deciphering context-specific resistance mechanisms and enhancing the tumor-specific immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaImmunotherapyBile Duct NeoplasmsHumansTumor MicroenvironmentAnimalsCancer VaccinesImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

combination therapyimmunotherapyintrahepatic cholangiocarcinomatumor immune microenvironment

Substanzen

Cancer VaccinesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
  • Collaborative Research Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
  • Shanghai Key Laboratory of Molecular Imaging and Digital and Intelligent Empowerment Biomedical Innovation Center, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.

ORCID-Profile: Hailong Wu

Zitieren

APA

Qi, H., Pan, J., & Wu, H. (2026). Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences, 27(14), 6228. https://doi.org/10.3390/ijms27146228

Vancouver

Qi H, Pan J, Wu H. Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences. 2026;27(14):6228. doi:10.3390/ijms27146228

BibTeX
@article{Qi2026,
  author = {Qi, Huimin and Pan, Jialin and Wu, Hailong},
  title = {Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6228},
  doi = {10.3390/ijms27146228}
}
Kostenlos starten →